Cetuximab (Erbitux) — Anti-EGFR Monoclonal Antibody for Colorectal Cancer
July 07, 2026
Cetuximab targets EGFR, inhibiting tumour cell proliferation in KRAS/NRAS wild-type colorectal cancer. Learn about its role and indications in treatment in China.
EGFR Targeting
Cetuximab (Erbitux) is a monoclonal anti-EGFR antibody that binds to the extracellular domain of EGFR and blocks cell proliferation signalling. It is most effective in colorectal cancer patients with no RAS mutations (KRAS/NRAS wild-type).
Indications
Used in: advanced colorectal cancer (combined with FOLFOX or FOLFIRI in RAS wild-type patients) and recurrent or advanced head-and-neck cancer (combined with chemotherapy or radiotherapy).
In China
Full RAS testing (KRAS/NRAS exon 2-4) is mandatory before Cetuximab use at Chinese oncology centres. International colorectal cancer patients travelling to China for treatment should bring genetic sequencing results to save time.
Disclaimer
Information is for reference only. Indications depend on RAS test results and physician assessment.
Related Images
